Cargando…
Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells
BACKGROUND: Pancreatic cancer remains the deadliest of all cancers, with a mortality rate of 91%. Gemcitabine is considered the gold chemotherapeutic standard, but only marginally improves life-span due to its chemical instability and low cell penetrance. A new paradigm to improve Gemcitabine’s ther...
Autores principales: | Papa, Anne-Laure, Basu, Sudipta, Sengupta, Poulomi, Banerjee, Deboshri, Sengupta, Shiladitya, Harfouche, Rania |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543259/ https://www.ncbi.nlm.nih.gov/pubmed/22998550 http://dx.doi.org/10.1186/1471-2407-12-419 |
Ejemplares similares
-
Nanotechnology-mediated targeting of tumor angiogenesis
por: Banerjee, Deboshri, et al.
Publicado: (2011) -
Hyaluronic Acid Layered Chimeric Nanoparticles: Targeting
MAPK-PI3K Signaling Hub in Colon Cancer Cells
por: Palvai, Sandeep, et al.
Publicado: (2017) -
Impairing Powerhouse in Colon Cancer Cells by Hydrazide–Hydrazone-Based
Small Molecule
por: Patil, Sohan, et al.
Publicado: (2018) -
Unbiased Phenotype-Based Screen Identifies Therapeutic Agents Selective for Metastatic Prostate Cancer
por: Chung, Ivy, et al.
Publicado: (2021) -
Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy
por: Xin, Xiaofei, et al.
Publicado: (2020)